Firebrick Pharma Accelerates Nasodine Rollout in Singapore with Key Partnerships

Strategic Expansion in Singapore

Firebrick Pharma Limited (ASX:FRE) has taken significant steps to broaden the market reach of its flagship product, Nasodine® Nasal Spray, in Singapore. The quarter ending December 2024 saw the company formalize a marketing representation agreement with Innorini Life Sciences, a Singapore-based firm tasked with promoting Nasodine to doctors and healthcare professionals. This move aims to build clinical awareness and endorsement ahead of broader retail availability.

Following this, Firebrick secured a pivotal retail partnership with Guardian Health & Beauty, the largest pharmacy chain in Singapore. This agreement ensures Nasodine’s presence across Guardian’s extensive network of pharmacies, marking a critical milestone in Firebrick’s commercialisation strategy in the region.

Distribution Infrastructure and Initial Shipments

To support the retail rollout, Firebrick entered into a distribution agreement with DKSH Singapore Pte Ltd, a leading market expansion services provider. DKSH will handle logistics and supply chain management, facilitating efficient delivery of Nasodine to Guardian pharmacies. In December 2024, Firebrick shipped initial retail pharmacy stocks to DKSH, enabling the commencement of sales in January 2025.

This coordinated approach between marketing, retail, and distribution partners underscores Firebrick’s commitment to establishing a robust presence in the Singaporean market, leveraging local expertise to accelerate product uptake.

Financial Position and Capital Raising

At the close of the quarter, Firebrick held $0.91 million in cash and cash equivalents, down from $1.14 million in the prior quarter. Operational cash outflows were $939,000, partially offset by a $774,000 capital raise through a share purchase plan and placement to existing shareholders. Payments to related parties increased slightly due to timing but remain consistent with prior periods.

Despite the net cash outflow, the company remains confident in its financial footing, citing the recent capital raise and anticipated revenue growth from the Singapore retail launch as key factors supporting ongoing operations.

Outlook and Market Potential

Firebrick reported a 111% increase in Nasodine online sales during the quarter, driven by both Singapore and US e-commerce channels. With the retail pharmacy launch underway in Singapore, the company expects a significant uplift in sales volumes from healthcare professional endorsements and consumer availability through Guardian pharmacies.

Looking ahead, Firebrick’s strategy to combine online growth with brick-and-mortar retail penetration could position Nasodine as a leading nasal spray product in the region. However, the company will need to closely monitor market reception and distribution effectiveness to sustain momentum.